| Literature DB >> 26470023 |
Zhenjiang Yao1, Yang Peng1, Xiaofeng Chen2, Jiaqi Bi3, Ying Li4, Xiaohua Ye1, Jing Shi5.
Abstract
BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most widespread and dangerous pathogens in healthcare settings. We carried out this case-control-control study at a tertiary care hospital in Guangzhou, China, to examine the antimicrobial susceptibility patterns, risk factors and clinical outcomes of MRSA infections.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26470023 PMCID: PMC4607165 DOI: 10.1371/journal.pone.0140604
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Comparison of antimicrobial susceptibility between MRSA and MSSA.
| Drug agent | MRSA (n = 57) | MSSA (n = 116) |
|
|---|---|---|---|
| No. (%) resistant isolates | No. (%) resistant isolates | ||
| GEN | 38 (66.67) | 8 (6.90) | <0.001 |
| IMI | 47 (82.46) | 0 (0.00) | <0.001 |
| CIP | 44 (77.19) | 17 (14.66) | <0.001 |
| LEV | 49 (85.96) | 85 (73.28) | 0.060 |
| PEN | 57 (100.00) | 103 (88.79) | 0.001 |
| VAN | 0 (0.00) | 0 (0.00) | NA |
| LIN | 0 (0.00) | 0 (0.00) | NA |
| AMO | 47 (82.46) | 0 (0.00) | <0.001 |
| AMP | 56 (98.25) | 100 (86.21) | 0.012 |
| OXA | 57 (100.00) | 0 (0.00) | <0.001 |
| S/T | 15 (26.32) | 0 (0.00) | <0.001 |
| CLI | 42 (73.68) | 25 (21.55) | <0.001 |
| Q/D | 3 (5.26) | 1 (0.86) | 0.081 |
| RIF | 5 (8.77) | 1 (0.86) | 0.009 |
| CHL | 14 (24.56) | 9 (7.76) | 0.002 |
| TET | 45 (78.95) | 33 (28.45) | <0.001 |
| CEF | 47 (82.46) | 0 (0.00) | <0.001 |
| ERY | 53 (92.98) | 41 (35.34) | <0.001 |
* NA: Not Available.
GEN: gentamicin; IMI: imipenem; CIP: ciprofloxacin; LEV: levofloxacin; PEN: penicillin; VAN: vancomycin; LIN: linezolid; AMO: amoxicillin; AMP: ampicillin; OXA: oxacillin; S/T: sulfamethoxazole/trimethoprim; CLI: clindamycin; Q/D: quinupristin/dalfopristin; RIF: rifampicin; CHL: chloramphenicol; TET: tetracycline; CEF: cefazolin; ERY: erythromycin.
Multivariate logistic regression analysis of risk factors for MRSA infections.
| Risk factor | MRSA versus MSSA | MRSA versus | ||
|---|---|---|---|---|
| aOR (95% CI) |
| aOR (95% CI) |
| |
| Prior hospitalizations≥3 | 2.8 (1.3–5.8) | 0.007 | ||
| COPD | 5.9 (1.7–20.7) | 0.006 | ||
| Respirator | 3.6 (1.0–12.9) | 0.046 | 3.8 (1.0–13.9) | 0.047 |
| Tracheal intubation | 8.2 (1.5–45.1) | 0.016 | ||
aOR: adjusted Odds Ratio; COPD: Chronic Obstructive Pulmonary Disease.
Cox proportional hazards analysis of the association between MRSA infections and length of hospital stay (compared with MSSA).
| Variable | Univariate Model | Multivariate Model | ||
|---|---|---|---|---|
| HR (95% CI) |
| HR (95% CI) |
| |
| MRSA | 1.8 (1.2–2.5) | 0.002 | 1.5 (1.0–2.2) | 0.046 |
| Prior hospitalizations≥3 | 1.5 (1.1–2.1) | 0.025 | 1.3 (0.9–1.9) | 0.156 |
| COPD | 1.2 (0.7–2.1) | 0.468 | 0.9 (0.5–1.7) | 0.840 |
| Respirator | 2.2 (1.2–3.9) | 0.010 | 1.7 (0.9–3.2) | 0.090 |
HR: Hazard Ratio; COPD: Chronic Obstructive Pulmonary Disease.
Fig 1Comparison of hospitalization rates for patients with MRSA infections and those with MSSA infections.
Adjusted for three or more prior hospitalizations, COPD and respirator use.
Cox proportional hazards analysis of the association between MRSA infections and length of hospital stay (compared with non-S. aureus).
| Variable | Univariate Model | Multivariate Model | ||
|---|---|---|---|---|
| HR (95% CI) |
| HR (95% CI) |
| |
| MRSA | 2.2 (1.5–3.2) | <0.001 | 1.8 (1.2–2.7) | 0.002 |
| Respirator | 2.2 (1.2–3.9) | 0.007 | 1.4 (0.7–2.6) | 0.310 |
| Tracheal intubation | 2.7 (1.3–5.5) | 0.007 | 1.8 (0.8–3.8) | 0.143 |
HR: Hazard Ratio.
Fig 2Comparison of hospitalization rates for patients with MRSA infections and those without S. aureus infections.
Adjusted for respirator use and tracheal intubation.